Clinical Trials | 08 May 2026
Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial
NEJM study shows strong protection across strains
NEJM study shows strong protection across strains
This is an exciting and meaningful milestone for GRIN Therapeutics
AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The Danish biotech company confirmed the global study will begin in the second half of 2026
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
By cutting pain crises & boosting haemoglobin
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Subscribe To Our Newsletter & Stay Updated
